Leerink analyst Geoffrey Porges says that the "confusing and somewhat lackluster data" presented over the weekend for Eylea's theoretical competitors should lift some of the overhang that Regeneron's stock has suffered from over the last 6 months. Novartis' (NVS) brolucizumab pivotal trial is confusing, and the data incomplete, and the analyst has serious doubts about the drug's approvability. Secondly, the addition of Ang2 inhibition to VEGF inhibition, while theoretically intriguing, has so far been of modest benefit despite Roche's (RHHBY) posturing, he contends. Porges reiterates an Outperform rating and $502 price target on Regeneron's shares.

TD Cowen analyst Yaron Werber raised the firm's price target on BeiGene (BGNE) to $236 from $235 and keeps a Buy rating on the shares. The firm updated its model to reflect lower collaborative revenue given termination of Novartis (NVS) agreement for tisle in Sep 2023.